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Topical administration is the most com-
mon route of ocular drug delivery. Despite
its apparent easy accessibility, the eye
is well protected from foreign materi-
als and drugs by a number of very
efficient mechanisms such as blinking,
induced lacrimation, tear turnover, naso-
lacrimal drainage, which cause rapid
removal of substances from the eye sur-
face and by the cornea, which forms
the physical-biological barrier (Figure 1).
Consequently, these protective mecha-
nisms and structural obstacle may cause
subtherapeutic drug levels at the tis-
sue target, particularly at retinal level.
Delivery of drugs to the posterior eye
is challenging, and there is an increas-
ing need for managing rapidly progressing
for posterior eye diseases, such as diabetic
retinopathy, age-related macular degen-
eration, and optic neuropathy (Bucolo
et al., 2012a,b; Musumeci et al., 2012).
Currently, the intravitreal route is widely
used to deliver therapeutic molecules to
the retina. However, frequent administra-
tion of drugs via this route can lead to
retinal detachment, endophthalmitis and
increased intraocular pressure. For this
reason ophthalmic drug delivery, particu-
larly targeted to posterior segment, is one
of the most challenging endeavors facing
the ocular pharmacologists. Topical route
represents a safer administration, there-
fore a major challenge to the scientists is
to overcome the ocular barriers and reach
the tissue target. Systemic route (e.g., oral,
parenteral) is also used to reach the eye,
though the drug transport across the ocu-
lar barriers (blood-aqueous barrier and
blood-retinal barrier) is quite difficult.
Under normal condition the human eye
can hold about 25–30μl of an ophthalmic
solution; however after a single blink the
volume is reduced to 7–10μl through
nasolacrimal drainage which cause the
drug to be systemically absorbed across
the nasal mucosa or the gastrointesti-
nal tract. A significant systemic loss from
topically applied drugs also occurs from
conjunctival absorption into the local cir-
culation (Figure 1). Tear turnover, which
can also be stimulated by factors such
as pH and tonicity of the formulation,
remove drug solution from the conjunc-
tival cul-de-sac in a few minutes. The
limited permeability of cornea also con-
tributes to the low absorption of ocular
drugs. The cornea consists of five dis-
tinct layers, with three of them, epithe-
lium, stroma, and endothelium, being the
main barriers to absorption. The lipophilic
corneal epithelium contains 5–7 layers of
cells each connected by tight junctions
and represents the rate-limiting barrier for
transcorneal diffusion of most hydrophilic
drugs; on the contrary the stroma, which
is mainly composed of hydrated colla-
gen, exerts a diffusional barrier to highly
lipophilic drugs. The endothelium is not
a significant barrier to the transcorneal
diffusion, in fact its permeability depends
on molecular weight rather than charac-
teristic of compound. Usually, 1–10% of
the instilled dose is absorbed ocularly and
roughly 1% reaches the aqueous humor
(Macha et al., 2003). In order to overcome
these problems, nanotechnology involv-
ing drug-loaded polymers particles has
been proposed as ophthalmic drug deliv-
ery systems that may control drug release
and maintain therapeutic levels over a
prolonged period of time. These systems
consist of nanoparticles (nanospheres and
nanopcapsules). Nanoparticles are poly-
meric colloidal drug carrier systems with a
size ranging from 10 nm to 1μm, in which
drugs are dissolved, entrapped, encapsu-
lated, or to which the drug are adsorbed
or attached. Nanospheres are small solid
monolithic spheres constituted of a dense
solid polymeric network, which develops a
large specific area. Nanocapsules are small
reservoirs consisting of a central cavity sur-
rounding by a polymeric membrane in
which molecules may be dissolved in an
oily core or adsorbed to a surface interface.
Properly formulated nanoparticles achieve
sustained drug release and prolonged ther-
apeutic effect if the formulation is retained
in the cul-de-sac after topical administra-
tion for a suitable period of time, and the
drug is released from the nanoparticles at a
proper rate. It is noteworthy that nanosys-
tems are also useful for intravitreal injec-
tion delaying the clearance of the drug and
reducing the need for repeated injections,
thereby lowering the risk of complications.
The success of nanoparticle systems
for ocular drug delivery may depend
on optimizing lipophilic-hydrophilic
properties of the polymer-drug system,
optimizing rates of biodegradation, and
safety. Polymers used for the preparation
of nanoparticles should be mucoad-
hesive and biocompatible. The choice
of polymer plays an important role in
the release kinetics of the drug from a
nanoparticle system. Ocular bioavailabil-
ity from a mucoadhesive dosage form
will depend on the polymer’s bioadhe-
sion characteristics, which are affected by
its swelling properties, hydration time,
molecular weight, and degree of crosslink-
ing. The binding of drug depends on
the physicochemical properties of the
molecule as well as of the nanoparticle
polymer, and also on the manufac-
turing process for these nanoparticle
systems. The polymers used in oph-
thalmic drug formulations are poly(alkyl
cyanoacrylates) (PACA) (Das et al., 1995),
poly(caprolactone) (PCL) (Losa et al.,
1993), poly(lactic acid) (PLA) (Giannavola
et al., 2003), poly(lactic-co-glycolic acid)
(PLGA) (Vega et al., 2008), chitosan (CS;
linear polysaccharide of randomly dis-
tributed β-(1–4)-linked D-glucosamine
and N-acetyl-D-glucosamine) (Diebold




(Bucolo et al., 2002, 2004; Pignatello et al.,
2002a,b), poly(acrylic acid) (PAA) and
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FIGURE 1 | Model showing the movement of drug into the eye after topical administration. BAB, blood-aqueous barrier; BRB, blood-retinal barrier.
hyaluronic acid (Sandri et al., 2006), and
modified polystyrene (Jani et al., 2007). In
several cases albumin (Irache et al., 2005)
gelatin (Vandervoort and Ludwig, 2004)
or lipid matrix (Attama et al., 2008) are
also used.
In general, the nanotechnology applied
to ocular drug delivery systems brought
to undoubted advantages such as, among
of others, higher solubility, higher area
available for dissolution, and higher dis-
solution rate. Other advantages from
nanosystems are higher corneal penetra-
tion and lower number of intraocular
injections for the anterior and posterior
ocular diseases, respectively. Ophthalmic
drug delivery, more than any other
route of administration, may benefit
to a full extent from the characteristics
of nano-sized drug particles. In con-
clusion, a multi-disciplinary approach
(from pharmacology to ophthalmol-
ogy and from biomaterial science to
pharmaceutical science) will bring, very
soon, to a clinical use of these innova-
tive nanosystems for the pharmacological
management of sight-threatening eye
diseases.
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